Jefferies analyst Brian Tanquilut initiated coverage of Pennant Group (PNTG) with a Buy rating and $30 price target The firm is bullish on the home health, saying the sector is a share gainer given its low-cost nature and patient preference for this site of care. As investors seek ways to play this thesis, Pennant sticks out given its low-teens EBITDA growth, driven by industry tailwinds and solid execution, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group management to meet with Oppenheimer
- Pennant Group management to meet with Truist
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- UnitedHealth (UNH) Divests Home Health and Hospice Assets Worth $146.5M to Pennant
- Pennant Group Expands with Strategic Acquisition in Southeast